SCHEMBL770313

SCHEMBL770313

O=C(CCCC(=O)N1CCCC2CCCCC21)NC1Cc2ccccc2C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.54
HRH3 Q9Y5N1 2/20 0.47
MTNR1A P48039 3/20 0.47
MTNR1B P49286 3/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DPP4 P27487 1/20 0.44
EPHX2 P34913 1/20 0.43
CHRM2 P08172 2/20 0.42
CHRM4 P08173 2/20 0.42
CHRM1 P11229 2/20 0.42
CHRM3 P20309 2/20 0.42
HSD11B1 P28845 2/20 0.42
EPHX1 P07099 1/20 0.42
HPGD P15428 2/20 0.41
GRM7 Q14831 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771390 0.84 SMN1; SMN2 (0.53) SMN1; SMN2EPHX2EPHX1HPGDALDH1A1
SCHEMBL772428 0.84 SMN1; SMN2 (0.53) SMN1; SMN2EPHX2EPHX1HPGDALDH1A1
SCHEMBL770314 0.83 TSHR (0.49) SMN1; SMN2HPGDALDH1A1
SCHEMBL771304 0.82 TSHR (0.56) MAPTSMN1; SMN2HPGDALDH1A1
SCHEMBL769700 0.81 MAPT (0.45) MAPTNPC1RAB9ASMN1; SMN2DPP4
SCHEMBL17690754 0.79 SMN1; SMN2 (0.40) NPC1RAB9ASMN1; SMN2DPP4EPHX2
SCHEMBL770615 0.78 DRD2 (0.49) NPC1RAB9ASMN1; SMN2HSD11B1
SCHEMBL770362 0.78 NPC1 (0.45) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL770291 0.78 GAA (0.56) HRH3NPC1RAB9ASMN1; SMN2DPP4
SCHEMBL802601 0.77 ALDH1A1 (0.49) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPT 618/4885HRH3 1687/4885MTNR1A 1745/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPT 638/4885HRH3 1698/4885MTNR1A 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.